36,694 Shares in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Acquired by CreativeOne Wealth LLC

CreativeOne Wealth LLC bought a new stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) during the 4th quarter, Holdings Channel reports. The firm bought 36,694 shares of the biopharmaceutical company’s stock, valued at approximately $766,000.

A number of other institutional investors also recently added to or reduced their stakes in the business. abrdn plc acquired a new position in shares of Catalyst Pharmaceuticals during the fourth quarter valued at $10,115,000. Arrowstreet Capital Limited Partnership increased its stake in Catalyst Pharmaceuticals by 131.4% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 698,152 shares of the biopharmaceutical company’s stock valued at $14,570,000 after buying an additional 396,506 shares during the period. Vanguard Group Inc. raised its position in shares of Catalyst Pharmaceuticals by 4.9% during the 4th quarter. Vanguard Group Inc. now owns 8,431,094 shares of the biopharmaceutical company’s stock worth $175,957,000 after buying an additional 390,116 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Catalyst Pharmaceuticals in the 4th quarter worth approximately $6,887,000. Finally, JPMorgan Chase & Co. lifted its stake in shares of Catalyst Pharmaceuticals by 80.3% in the 4th quarter. JPMorgan Chase & Co. now owns 736,197 shares of the biopharmaceutical company’s stock worth $15,364,000 after acquiring an additional 327,936 shares during the period. Institutional investors and hedge funds own 79.22% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. StockNews.com raised Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, February 28th. Baird R W raised Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Monday, February 3rd. HC Wainwright reaffirmed a “buy” rating and set a $35.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Robert W. Baird lifted their target price on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an “outperform” rating in a report on Monday, March 3rd. Finally, Stephens restated an “overweight” rating and set a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $32.29.

Catalyst Pharmaceuticals Stock Up 1.5 %

NASDAQ:CPRX opened at $22.52 on Friday. The stock has a fifty day simple moving average of $22.61 and a 200 day simple moving average of $22.05. The firm has a market capitalization of $2.75 billion, a price-to-earnings ratio of 19.08, a price-to-earnings-growth ratio of 3.31 and a beta of 0.79. Catalyst Pharmaceuticals, Inc. has a 1-year low of $14.47 and a 1-year high of $26.16.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 44,904 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total transaction of $991,929.36. Following the transaction, the insider now directly owns 68,873 shares in the company, valued at approximately $1,521,404.57. The trade was a 39.47 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Brian Elsbernd sold 62,975 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total value of $1,447,165.50. Following the completion of the sale, the insider now owns 188,564 shares of the company’s stock, valued at $4,333,200.72. The trade was a 25.04 % decrease in their position. The disclosure for this sale can be found here. Insiders own 11.00% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.